- Cocrystal Pharma Inc COCP has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19.
- FDA's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 trials for CDI-45205.
- Related Link: Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains.
- CDI-45205 is among protease inhibitors obtained under an exclusive license agreement with Kansas State University Research Foundation (KSURF) in 2020.
- CDI-45205 and several analogs showed potent in vitro activity against the variants, surpassing the activity observed with the original Wuhan strain.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: COCP shares are up 5.92% at $0.95 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 1 TrialPhase 2 Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
